Accordingly, the inhibition of TLR4 and its downstream signaling molecules has been shown to prevent or to treat NEC in preclinical studies, while strategies to enhance enteric nervous system activity can attenuate NEC in preclinical models. This evidence concerns the gene TLR4 and necrotizing enterocolitis.